Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DT52FI
|
|||
| Drug Name |
MYK-491
|
|||
| Synonyms |
Danicamtiv; UNII-7B2CS922HI; 7B2CS922HI; SAR440181; 1970972-74-7; Danicamtiv [INN]; Danicamtiv [USAN]; Danicamtiv (USAN/INN); MYK491; CHEMBL4594304; SCHEMBL17942536; WHO 10942; SAR-440181; HY-109128; CS-0086762; D11824; (R)-4-(1-((3-(Difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide; 1-Piperidinecarboxamide, 4-((1R)-1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-3-isoxazolyl-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Dilated cardiomyopathy [ICD-11: BC43.0; ICD-10: I42.0] | Phase 2 | [1] | |
| Company |
MyoKardia; Sanofi
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H20F3N5O4S
|
|||
| Canonical SMILES |
CC(C1CCN(CC1)C(=O)NC2=NOC=C2)(F)S(=O)(=O)C3=CN(N=C3C(F)F)C
|
|||
| InChI |
1S/C16H20F3N5O4S/c1-16(19,29(26,27)11-9-23(2)21-13(11)14(17)18)10-3-6-24(7-4-10)15(25)20-12-5-8-28-22-12/h5,8-10,14H,3-4,6-7H2,1-2H3,(H,20,22,25)/t16-/m1/s1
|
|||
| InChIKey |
NREKKBAMVWQRES-MRXNPFEDSA-N
|
|||
| CAS Number |
CAS 1970972-74-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myosin (MYO) | Target Info | Activator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03447990) Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491. U.S. National Institutes of Health. | |||
| REF 2 | Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. Eur J Heart Fail. 2020 Sep;22(9):1649-1658. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.